Publikationen von Prof. Dr. Christof von Kalle

Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T. BRAF inhibition in hairy cell leukemia with low dose vemurafenib.Blood. 2016 Mar 3. pii: blood-2015-11-680074.

1. Oliveira G, Ruggiero E, Stanghellini MT, Cieri N, D'Agostino M, Fronza R, Lulay C, Dionisio F, Mastaglio S, Greco R, Peccatori J, Aiuti A, Ambrosi A, Biasco L, Bondanza A, Lambiase A, Traversari C, Vago L, von Kalle C, Schmidt M, Bordignon C, Ciceri F, Bonini C. Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Sci Transl Med 2015 7(317):317ra198. Erratum in: Sci Transl Med 2015 7(319):319er9.

2. Naldini L, Schumacher T, von Kalle C, Thrasher A, Bordignon C. Toward Clinical Translation of New Gene Targeting Technologies for Correcting Inherited Mutations and Empowering Adoptive Immunotherapy of Cancer (SUPERSIST). Human Gene Therapy. Clinical Development 2015; 26(2):95-97.

3. Kordes M, Röring M, Heining C, Braun S, Hutter B, Richter D, Geörg C, Scholl C, Gröschel S, Roth W, Rosenwald A, Geissinger E, von Kalle C, Jäger D, Brors B, Weichert W, Grüllich C, Glimm H, Brummer T, Fröhling S. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. Leukemia 2015 Nov 19. doi: 10.1038/leu.2015.319. [Epub ahead of print].

4. Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Gabriel R, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR. Evaluation of TCR Gene Editing achieved by TALENs, CRISPR/Cas9 and megaTAL nucleases. Mol Ther 2015 Oct 27. doi: 10.1038/mt.2015.197. [Epub ahead of print].

5. Molina-Estevez FJ, Nowrouzi A, Lozano M, Galy A, Charrier S, von Kalle C, Guenechea G, Bueren JA, Schmidt M. Lentiviral-mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. Curr Gene Ther 2015; 15(6):550-562.

6. Ruggiero E, Nicolay JP, Fronza R, Arens A, Paruzynski A, Nowrouzi A, Ürenden G, Lulay C, Schneider S, Goerdt S, Glimm H, Krammer PH, Schmidt M, von Kalle C. High-resolution analysis of the human T-cell receptor repertoire. Nat Commun 2015; 6:8081. DOI: 10.1038/ncomms9081.

7. Grömminger S, Erkan S, Schöck U, Stangier K, Bonnet J, Schloo R, Schubert A, Prott EC, Knoll U, Stumm M, von Kalle C, Hofmann W. The Influence of Low Molecular Weight Heparin Medication on Plasma DNA in Pregnant Women. Prenat Diagn 2015; Aug 6. doi: 10.1002/pd.4668. [Epub ahead of print].

8. Schuol S, Schickhardt C, Wiemann S, Bartram CR, Tanner K, Eils R, Meder B, Richter D, Glimm H, von Kalle C, Winkler EC. So rare we need to hunt for them: reframing the ethical debate on incidental findings. Genome Med 2015; Jul 30;7(1):83. doi: 10.1186/s13073-015-0198-3. eCollection 2015.

9. Sundarasetty BS, Kloess S, Oberschmidt O, Naundorf S, Kuehlcke K, Daenthanasanmak A, Gerasch L, Figueiredo C, Blasczyk R, Ruggiero E, Fronza R, Schmidt M, von Kalle C, Rothe M, Ganser A, Koehl U, Stripecke R. Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. J Transl Med 2015; 13:240.

10. Richards DM, Ruggiero E, Hofer AC, Sefrin JP, Schmidt M, von Kalle C, Feuerer M. The Contained Self-Reactive Peripheral T Cell Repertoire: Size, Diversity, and Cellular Composition. J Immunol 2015; 195(5):2067-79.

11. Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T. Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood 2015; 126(8):1005-8.

12. Giordano FA, Appelt JU, Link B, Gerdes S, Lehrer C, Scholz S, Paruzynski A, Roeder I, Wenz F, Glimm H, von Kalle C, Grez M, Schmidt M, Laufs S. High-throughput monitoring of integration site clonality in preclinical and clinical gene therapy studies. Mol Ther Methods Clin Dev 2015 Apr 1;2:14061. doi: 10.1038/mtm.2014.61. eCollection 2015.

13. Daenthanasanmak A, Salguero G, Sundarasetty BS, Waskow C, Cosgun KN, Guzman CA, Riese P, Gerasch L, Schneider A, Ingendoh A, Messerle M, Gabaev I, Woelk B, Ruggiero E, Schmidt M, von Kalle C, Figueiredo C, Eiz-Vesper B, von Kaisenberg C, Ganser A, Stripecke R. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev 2015 Jan 7;1:14060. doi: 10.1038/mtm.2014.60. eCollection 2015.

14. Sundarasetty BS, Chan L, Darling D, Giunti G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E, Schmidt M, von Kalle C, Rothe M, Hoon DS, Gerasch L, Figueiredo C, Koehl U, Blasczyk R, Gutzmer R, Stripecke R. Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2 positive melanoma. Gene Ther 2015; 22(9):707-20.

15. Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, Karapanagiotou-Schenkel I, von Kalle C, Jäger D, Büchler MW, Schemmer P. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial. BMC Cancer 2015; 15(1):392.

16. Corrigan-Curay J, O'Reilly M, Kohn DB, Cannon PM, Bao G, Bushman FD, Carroll D, Cathomen T, Joung JK, Roth D, Sadelain M, Scharenberg AM, von Kalle C, Zhang F, Jambou R, Rosenthal E, Hassani M, Singh A, Porteus MH. Genome editing technologies: defining a path to clinic. Mol Ther 2015; 23(5):796-806.

17. Bergot AS, Chaara W, Ruggiero E, Mariotti-Ferrandiz E, Dulauroy S, Schmidt M, von Kalle C, Six A, Klatzmann D. TCR sequences and tissue distribution discriminate the subsets of naïve and activated/memory Treg cells in mice. Eur J Immunol 2015; 45(5):1524-34.

18. Gabriel, R, von Kalle, C, Schmidt, M. Mapping the precision of genome editing. Nat Biotechnol 2015; 33(2):150-152.

19. Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, Alhan C, de Loosdrecht AA, Schwäble J, Pfluger T, Tchinda J, Schmugge M, Jauch A, Naundorf S, Kühlcke K, Notheis G, Güngor T, Kalle CV, Schmidt M, Grez M, Seger R, Reichenbach J. Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing. Curr Gene Ther 2015; 15(4):416-27.

20. Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Fanconi Anemia Gene Editing by the CRISPR/Cas9 System. Hum Gene Ther 2015; 26(2):114-26; Epub ahead of print 2014 Dec 29.

21. Negre O, Bartholomae C, Beuzard Y, Cavazzana M, Christiansen L, Courne C, Deichmann A, Denaro M, Dreuzy Ed, Finer M, Fronza R, Gillet-Legrand B, Joubert C, Kutner R, Leboulch P, Maouche L, Paulard A, Pierciey FJ, Rothe M, Ryu B, Schmidt M, Kalle Cv, Payen E, Veres G. Preclinical Evaluation of Efficacy and Safety of an Improved Lentiviral Vector for the Treatment of β-Thalassemia and Sickle Cell Disease. Curr Gene Ther 2015; 15(1):64-81.

22. Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB. Identification of NY-BR-1-specific CD4+ T cell epitopes using HLA-transgenic mice. Int J Cancer 2015; 136(11):2588-97. Epub ahead of print 2014 Nov 12.

23. Papanikolaou E, Paruzynski A, Kasampalidis I, Deichmann A, Stamateris E, Schmidt M, Kalle CV, Anagnou NP. Cell Cycle Status of CD34+ Hemopoietic Stem Cells Determines Lentiviral Integration in Actively Transcribed and Development-related Genes. Mol Ther 2015; 23(4):683-96. Epub ahead of print 2014 Dec 19.

24. Qamar Saeed M, Dufour N, Bartholmae C, Sieranska U, Knopf M, Thierry E, Thierry S, Delelis O, Grandchamp N, Pilet H, Ravassard P, Massonneau J, Pflumio F, von Kalle C, Lachapelle F, Bemelmans AP, Schmidt M, Serguera C. Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant. Mol Ther Nucleic Acids 2014 Dec 2;3:e213.

25. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umanksy V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G. Mol Ther 2014; 22(11):1949-59.

26. Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jäger D, von Kalle C, Ungerechts G. MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus. Cancer Gene Ther 2014; 21(9):373-8010.

27. Northcott PA, Lee C, Zichner T, Stütz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, Jones DT, Kool M, Remke M, Cavalli FM, Zuyderduyn S, Bader GD, VandenBerg S, Esparza LA, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch CD, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz HJ, Risch T, Yaspo ML, Weber UD, Bartholomae CC, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann MU, Ebinger M, Grimes HL, Robinson GW, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik AE, von Deimling A, Witt O, Eils R, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Korbel JO, Wechsler-Reya RJ, Pfister SM. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 2014; 24; 511(7510):428-34.

28. Valentini V, Abrahamsson PA, Aranda SK, Astier A, Audisio RA, Boniol M, Bonomo L, Brunelli A, Bultz B, Chiti A, De Lorenzo F, Eriksen JG, Goh V, Gospodarowicz MK, Grassi L, Kelly J, Kortmann RD, Kutluk T, Plate A, Poston G, Saarto T, Soffietti R, Torresin A, van Harten WH, Verzijlbergen JF, von Kalle C, Poortmans P. Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014). Ann Oncol 2014; 25(9):1863-5.

29. Gabriel R, Kutschera I, Bartholomae CC, von Kalle C, Schmidt M. Linear amplification mediated PCR - localization of genetic elements and characterization of unknown flanking DNA. J Vis Exp 2014 Jun 25;(88). doi: 10.3791/51543.

30. von Kalle C, Deichmann A, Schmidt M. Vector integration and tumorigenesis. Hum Gene Ther 2014; 25(6):475-81.

31. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M. Reply to: NGS library preparation may generate artifactual integration sites of AAV vectors. Nat Med 2014; 20(6):578-9.

32. Hovestadt V, Jones DT, Picelli S, Wang W, Kool M, Northcott PA, Sultan M, Stachurski K, Ryzhova M, Warnatz HJ, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber UD, Bartholomae CC, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor MD, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya RJ, Eils R, Yaspo ML, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 2014; 510(7506):537-41.

33. Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM; ICGC PedBrain Tumor Project. Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell 2014; 25(3):393-405.

34. Lu-Nguyen NB, Broadstock M, Schliesser MG, Bartholomae C, von Kalle C, Schmidt M, Yáñez-Muñoz RJ. Transgenic expression of human glial cell line-derived neurotrophic factor (hGDNF) from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease. Hum Gene Ther 2014; 25(7):631-41.

35. Braun CJ, Boztug K, Paruzynski A, Witzel M, Schwarzer A, Rothe M, Modlich U, Beier R, Göhring G, Steinemann D, Fronza R, Ball CR, Haemmerle R, Naundorf S, Kühlcke K, Rose M, Fraser C, Mathias L, Ferrari R, Abboud MR, Al-Herz W, Kondratenko I, Maródi L, Glimm H, Schlegelberger B, Schambach A, Albert MH, Schmidt M, von Kalle C, Klein C. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 2014; 6(227):227ra33.

36. Ketzer P, Kaufmann JK, Engelhardt S, Bossow S, von Kalle C, Hartig JS, Ungerechts G, Nettelbeck DM. Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. Proc Natl Acad Sci U S A 2014; 111(5):E554-62.

37. Cesana D, Ranzani M, Volpin M, Bartholomae C, Duros C, Artus A, Merella S, Benedicenti F, Sergi LS, Sanvito F, Brombin C, Nonis A, Serio CD, Doglioni C, von Kalle C, Schmidt M, Cohen-Haguenauer O, Naldini L, Montini E. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol Ther 2014; 22(4):774-85.

38. Pañeda MA, Lopez-Franco E, Kaeppel C, Unzu C, Gil-Royo AG, D'Avola D, Beattie SG, Olague C, Ferrero R, Sampedro A, Mauleon I, Hermening S, Salmon F, Benito A, Gavira JJ, Cornet ME, Municio MD, von Kalle C, Petry H, Prieto J, Schmidt M, Fontanellas A, Gonzalez-Aseguinolaza G. Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria. Hum Gene Ther 2013; 24(12):1007-17.

39. Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, Te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. Br J Haematol 2013; 163(4):496-500.

40. Hadaschik B, Pahernik S, Grüllich C, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Urology in the concept of comprehensive cancer centers. Urologe A 2013; 52(9):1283-9.

41. Suwanmanee T, Hu G, Gui T, Bartholomae CC, Kutschera I, von Kalle C, Schmidt M, Monahan PE, Kafri T. Integration-deficient lentiviral vectors expressing codon-optimized R338LhFIX restore normal hemostasis in hemophilia B mice. Mol Ther 2013; 22(3):567-74.

42. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S, Benedicenti F, Vallanti G, Biasco L, Leo S, Kabbara N, Zanetti G, Rizzo WB, Mehta NA, Cicalese MP, Casiraghi M, Boelens JJ, Del Carro U, Dow DJ, Schmidt M, Assanelli A, Neduva V, Di Serio C, Stupka E, Gardner J, von Kalle C, Bordignon C, Ciceri F, Rovelli A, Roncarolo MG, Aiuti A, Sessa M, Naldini L. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science 2013; 341(6148):1233158.

43. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, Dionisio F, Calabria A, Giannelli S, Castiello MC, Bosticardo M, Evangelio C, Assanelli A, Casiraghi M, Di Nunzio S, Callegaro L, Benati C, Rizzardi P, Pellin D, Di Serio C, Schmidt M, Von Kalle C, Gardner J, Mehta N, Neduva V, Dow DJ, Galy A, Miniero R, Finocchi A, Metin A, Banerjee P, Orange J, Galimberti S, Valsecchi MG, Biffi A, Montini E, Villa A, Ciceri F, Roncarolo MG, Naldini L. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Science 2013; 341(6148):1233151.

44. Stein S, Scholz S, Schwaeble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Mueller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson Jr RG, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kuehlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M. From Bench to Bedside: Preclinical Evaluation of a SIN gammaretroviral vector for the Gene Therapy of X-linked Chronic Granulomatous Disease. Hum Gene Ther Clin Dev 2013; 24(2):86-98.

45. Jones DT, Hutter B, Jäger N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso AM, Stütz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ralser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P; the International Cancer Genome Consortium PedBrain Tumor Project, Pfister SM. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013; 45(8):927-32.

46. Kaeppel C, Beattie SG, Fronza R, van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, von Kalle C, Petry H, Gaudet D, Schmidt M. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013; 19(7):889-91.

47. Tubsuwan A, Abed S, Deichmann A, Kardel MD, Bartholomä C, Cheung A, Negre O, Kadri Z, Fucharoen S, von Kalle C, Payen E, Chrétien S, Schmidt M, Eaves CJ, Leboulch P, Maouche-Chrétien L. Parallel Assessment of Globin Lentiviral Transfer in Induced Pluripotent Stem Cells and Adult Hematopoietic Stem Cells Derived from the Same Transplanted β-Thalassemia Patient. Stem Cells 2013; 163(4):496-500.

48. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T. Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia. J Clin Oncol 2013; 31(19):e300-3.

49. Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. GM-CSF-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24(7):644-54.

50. Hüllein J, Jethwa A, Stolz T, Blume C, Sellner L, Sill M, Langer C, Jauch A, Paruzynski A, von Kalle C, Schmidt M, Glimm H, Zenz T. Next-generation sequencing of cancer consensus genes in lymphoma. Leuk Lymphoma 2013; 54(8):1831-5.

51. Osborn MJ, Starker CG, McElroy AN, Webber BR, Riddle MJ, Xia L, Defeo AP, Gabriel R, Schmidt M, von Kalle C, Carlson DF, Maeder ML, Joung JK, Wagner JE, Voytas DF, Blazar BR, Tolar J. TALEN-based Gene Correction for Epidermolysis Bullosa. Mol Ther 2013; 1(6):1151-9.

52. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013; 23(2):159-70.

53. Ranzani M, Cesana D, Bartholomae CC, Sanvito F, Pala M, Benedicenti F, Gallina P, Sergi LS, Merella S, Bulfone A, Doglioni C, von Kalle C, Kim YJ, Schmidt M, Tonon G, Naldini L, Montini E. Lentiviral vector-based insertional mutagenesis identifies genes associated with liver cancer. Nat Methods 2013; 10(2):155-61.

54. Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, Hernandez RJ, Benedicenti F, Radrizzani M, Salomoni M, Ranzani M, Bartholomae CC, Vicenzi E, Finocchi A, Bredius R, Bosticardo M, Schmidt M, von Kalle C, Montini E, Biffi A, Roncarolo MG, Naldini L, Villa A, Aiuti A. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich Syndrome. Mol Ther 2013; 21(1):175-84. Epub 2012, Feb 28.

55. Nowrouzi A, Cheung WT, Li T, Zhang X, Arens A, Paruzynski A, Waddington SN, Osejindu E, Reja S, von Kalle C, Wang Y, Al-Allaf F, Gregory L, Themis M, Holder M, Dighe N, Ruthe A, Buckley SMK, Bigger B, Montini E, Thrasher AJ, Andrews R, Roberts, TP, Newbold RF, Coutelle C, Schmidt M (co-senior author), Themis M. The Fetal Mouse Is a Sensitive Genotoxicity Model That Exposes Lentiviral-associated Mutagenesis Resulting in Liver Oncogenesis. Molecular Therapy 2013; 21(2):324-37. Epub 2012, Nov 13.

56. Cornils K, Bartholomae CC, Thielecke L, Lange C, Arens A, Glauche I, Mock U, Riecken K, Gerdes S, von Kalle C, Schmidt M, Roeder I, Fehse B. Comparative clonal analysis of reconstitution kinetics after transplantation of haematopoietic stem cells gene-marked with a lentiviral SIN or a γ-retroviral LTR vector. Exp Hematol 2013; 41(1):28-38. Epub 2012, Sep 15.

57. Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G. Chemovirotherapy of Malignant Melanoma with a Targeted and Armed Oncolytic Measles Virus. J Invest Dermatol 2013; 133(4):1034-422012 Epub 2012 Dec 6.

58. Gabriel R, Schmidt M, von Kalle C. Integration of retroviral vectors. Curr Opin Immunol 2012; 24(5):592-597.

59. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Paolo Tonini G, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Peter Collins V, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488(7409):100-5.

60. Martins VC, Ruggiero E, Schlenner SM, Madan V, Schmidt M, Fink PJ, von Kalle C, Rodewald HR. Thymus-autonomous T cell development in the absence of progenitor import. J Exp Med 2012; 209(8):1409-17.

61. Zavidij O, Ball CR, Herbst F, Oppel F, Fessler S, Schmidt M, von Kalle C, Glimm H. Stable Long-Term Blood Formation by Stem Cells in Murine Steady-State Hematopoiesis. Stem Cells 2012; 30(9):1961-70.

62. Herpel E, Koleganova N, Schreiber B, Walter B, Kalle CV, Schirmacher P. Structural requirements of research tissue banks derived from standardized project surveillance. Virchows Arch 2012; 461(1):79-86.

63. Corrigan-Curay J, Cohen-Haguenauer O, O'Reilly M, Ross SR, Fan H, Rosenberg N, Somia N, King N, Friedmann T, Dunbar C, Aiuti A, Naldini L, Baum C, von Kalle C, Kiem HP, Montini E, Bushman F, Sorrentino BP, Carrondo M, Malech H, Gahrton G, Shapiro R, Wolff L, Rosenthal E, Jambou R, Zaia J, Kohn DB. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol Ther 2012; 20(6):1084-94.

64. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366(21):2038-40.

65. Arens A, Appelt JU, Bartholomae CC, Gabriel R, Paruzynski A, Gustafson D, Cartier N, Aubourg P, Deichmann A, Glimm H, von Kalle C, Schmidt M. Bioinformatic Clonality Analysis of Next-Generation Sequencing-Derived Viral Vector Integration Sites. Hum Gene Ther Methods 2012; 23(2):111-8.

66. Herbst F, Ball CR, Tuorto F, Nowrouzi A, Wang W, Zavidij O, Dieter SM, Fessler S, van der Hoeven F, Kloz U, Lyko F, Schmidt M, von Kalle C, Glimm H. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. Mol Ther 2012; 20(5):1014-21.

67. Pincha M, Sai Sundarasetty B, Salguero G, Gutzmer R, Garritsen H, Macke L, Schneider A, Lenz D, Figueiredo C, Blasczyk R, Ruggiero E, Schmidt M, von Kalle C, Puff C, Modlich U, von der Leyen H, Wicke DC, Ganser A, Stripecke R. Identity, potency, in vivo viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods 2012; 23(1):38-55.

68. Nowrouzi A, Penaud-Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, Kalle Cv, Snyder RO, Schmidt M. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 2012; 20(6):1177-86.

69. Schossig A, Wolf NI, Fischer C, Fischer M, Stocker G, Pabinger S, Dander A, Steiner B, Tönz O, Kotzot D, Haberlandt E, Amberger A, Burwinkel B, Wimmer K, Fauth C, Grond-Ginsbach C, Koch MJ, Deichmann A, von Kalle C, Bartram CR, Kohlschütter A, Trajanoski Z, Zschocke J. Mutations in ROGDI Cause Kohlschütter-Tönz Syndrome. Am J Hum Genet 2012; 90(4):701-7.

70. Grüllich C, von Kalle C. Recent developments and future perspectives of personalized oncology. Onkologie 2012; 35 Suppl 1:4-7.

71. Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, von Kalle C, Ungerechts G. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Cancer Gene Ther 2012; 19(3):181-91.

72. Glimm H, Ball CR, von Kalle C. You can count on this: barcoded hematopoietic stem cells. Cell Stem Cell 2011; 9(5):390-2.

73. Abel U, Deichmann A, Nowrouzi A, Gabriel R, Bartholomae CC, Glimm H, von Kalle C, Schmidt M. Analyzing the number of common integration sites of viral vectors - new methods and computer programs. PLoS One 2011; 6(10):e24247.

74. Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, Abel U, Arens A, Weichert W, Brand K, Koch M, Weitz J, Schmidt M, von Kalle C, Glimm H. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9(4):357-65.

75. Kang HJ, Bartholomae CC, Paruzynski A, Arens A, Kim S, Yu SS, Hong Y, Joo CW, Yoon NK, Rhim JW, Kim JG, von Kalle C, Schmidt M, Kim S, Ahn HS. Retroviral gene therapy for X-linked chronic granulomatous disease: Results From Phase I/II Trial. Mol Ther 2011; 19(11):2092-101.

76. Deichmann A, Brugman MH, Bartholomae CC, Schwarzwaelder K, Verstegen MM, Howe SJ, Arens A, Ott MG, Hoelzer D, Seger R, Grez M, Hacein-Bey-Abina S, Cavazzana-Calvo M, Fischer A, Paruzynski A, Gabriel R, Glimm H, Abel U, Cattoglio C, Mavilio F, Cassani B, Aiuti A, Dunbar CE, Baum C, Gaspar HB, Thrasher AJ, von Kalle C, Schmidt M, Wagemaker G. Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 2011; 19(11):2031-9.

77. Gabriel R, Lombardo A, Arens A, Miller JC , Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, Holmes MC, Gregory PD, Glimm H, Schmidt M, Naldini L, von Kalle C. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotech 2011; 29(9):816-23.

78. Huston MW, van Til NP, Visser TP, Arshad S, Brugman MH, Cattoglio C, Nowrouzi A, Li Y, Schambach A, Schmidt M, Baum C, von Kalle C, Mavilio F, Zhang F, Blundell MP, Thrasher AJ, Verstegen MM Wagemaker G. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther 2011; 19(10):1867-77.

79. Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G. Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 2011; 18(8):598-608.

80. Mattar CN, Nathwani AC, Waddington SN, Dighe N, Kaeppel C, Nowrouzi A, McIntosh J, Johana NB, Ogden B, Fisk NM, Davidoff AM, David A, Peebles D, Valentine MB, Appelt JU, von Kalle C, Schmidt M, Biswas A, Choolani M, Chan JK. Stable Human FIX Expression After 0.9G Intrauterine gene transfer of self-complementary Adeno-associated viral vector 5 and 8 in Macaques. Mol Ther 2011; 19(11):1950-60.

81. Mátrai J, Cantore A, Bartholomae CC, Annoni A, Wang W, Acosta-Sanchez A, Samara-Kuko E, De Waele L, Ma L, Genovese P, Damo M, Arens A, Goudy K, Nichols TC, von Kalle C, L Chuah MK, Roncarolo MG, Schmidt M, Vandendriessche T, Naldini L. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 2011; 53(5):1696-707.

82. Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G. MicroRNA-sensitive Oncolytic Measles Viruses for Cancer-specific Vector Tropism. Mol Ther 2011; 19(6):1097-106.

83. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, Cesani M, Benedicenti F, Plati T, Rubagotti E, Merella S, Capotondo A, Sgualdino J, Zanetti G, von Kalle C, Schmidt M, Naldini L, Montini E. Lentiviral-vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117(20):5332-9.

84. Bartholomae CC, Arens A, Balaggan KS, Yáñez-Muñoz RJ, Montini E, Howe SJ, Paruzynski A, Korn B, Appelt JU, Macneil A, Cesana D, Abel U, Glimm H, Naldini L, Ali RR, Thrasher AJ, von Kalle C (co-corresponding), Schmidt M. Lentiviral vector integration profiles differ in rodent postmitotic tissues. Mol Ther 2011; 19(4):703-10.

85. Okazuka K, Beard BC, Emery DW, Schwarzwaelder K, Spector MR, Sale GE, von Kalle C, Kiem HP, Blau CA. Long-term regulation of genetically modified primary hematopoietic cells in dogs. Mol Ther 2011; 19(7):1287-94.

86. Giordano FA, Sorg UR, Appelt JU, Lachmann N, Bleier S, Roeder I, Kleff V, Flasshove M, Zeller WJ, Allgayer H, von Kalle C, Fruehauf S, Moritz T, Laufs S. Clonal inventory screens uncover monoclonality following serial transplantation of MGMTP140K transduced stem cells and dose-intense chemotherapy. Hum Gene Ther 2011; 22(6):697-710.

87. Biasco L, Ambrosi A, Pellin D, Bartholomae C, Brigida I, Roncarolo MG, Di Serio C, von Kalle C, Schmidt M, Aiuti A. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med 2011; 3(2):89-101.

88. Herbst F, Ball CR, Zavidij O, Fessler S, Schmidt M, Veelken H, von Kalle C, Glimm H. 10-Year stability of clinical-grade serum-free gamma-retroviral vector-containing medium. Gene Ther 2011; 18(2):210-2.

89. Cattoglio C, Maruggi G, Bartholomae C, Malani N, Pellin D, Cocchiarella F, Magnani Z, Ciceri F, Ambrosi A, von Kalle C, Bushman FD, Bonini C, Schmidt M, Mavilio F, Recchia A. High-definition mapping of retroviral integration sites defines the fate of allogeneic T cells after donor lymphocyte infusion. PLoS One 2010; 5(12):e15688.

90. Cartier N, Hacein-Bey-Abina S, von Kalle C, Bougnères P, Fischer A, Cavazzana-Calvo M, Aubourg P. Gene therapy of x-linked adrenoleukodystrophy using hematopoietic stem cells and a lentiviral vector. Bull Acad Natl Med 2010; 194(2):255-64; discussion 264-8. French.

91. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez AI, Dewey R, Böhm M, Ball CR, Glimm H, Nowrouzi A, Naundorf S, Kühlcke K, Blasczyk R, Kondratenko I, Maródi L, Orange JS, von Kalle C, Klein C. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363(20):1918-27.

92. Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten O, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweitzer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M. Relevance of an Academic GMP Pan-European Vector Infra-structure (PEVI). Curr Gene Ther 2010; 10(6):414-22.

93. Kane NM, Nowrouzi A, Mukherjee S, Blundell MP, Greig JA, Lee WK, Houslay MD, Milligan G, Mountford JC, von Kalle C, Schmidt M, Thrasher AJ, Baker AH. Lentivirus-mediated reprogramming of somatic cells in the absence of transgenic transcription factors. Mol Ther 2010; 18(12):2139-45.

94. Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, Wang W, Wolf S, Glimm H, Schmidt M, von Kalle C Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc 2010; 5(8):1379-95.

95. International Cancer Genome Consortium. Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, et al. International network of cancer genome projects. Nature 2010; 464(7291):993-8.

96. Zavidij O, Ball CR, Herbst F, Fessler S, Schmidt M, von Kalle C, Glimm H. Hematopoietic activity of human short term repopulating cells in mobilized peripheral blood cell transplants is restricted to the first 5 months after transplantation. Blood 2010; 115(24):5023-5.

97. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, Schmidt M, Krämer A, Schwäble J, Glimm H, Koehl U, Preiss C, Ball C, Martin H, Göhring G, Schwarzwaelder K, Hofmann WK, Karakaya K, Tchatchou S, Yang R, Reinecke P, Kühlcke K, Schlegelberger B, Thrasher AJ, Hoelzer D, Seger R, von Kalle C (co-corresponding), Grez M. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16(2):198-204.

98. Tacke M, Ball CR, Schmidt M, Klingenberg S, Maurer B, Fessler S, Eaves C, von Kalle C, Glimm H. The inherent differentiation program of short term hematopoietic repopulating cells changes during human ontogeny. Stem Cells Dev 2010; 19(5):621-628.

99. Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, Howe SJ, Recchia A, Cattoglio C, Wang W, Faber K, Schwarzwaelder K, Kirsten R, Deichmann A, Ball CR, Balaggan KS, Yáñez-Muñoz RJ, Ali RR, Gaspar HB, Biasco L, Aiuti A, Cesana D, Montini E, Naldini L, Cohen-Haguenauer O, Mavilio F, Thrasher AJ, Glimm H, von Kalle C, Saurin W, Schmidt M. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med 2009; 15(12):1431-6.

100. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrère F, Blanche S, Audit M, Payen E, Leboulch P, l'Homme B, Bougnères P, von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326(5954):818-23.

101. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, Doglioni C, Di Serio C, von Kalle C, Naldini L. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119(4):964-75.

102. Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA. Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine 2009; 15(3):285-92.

103. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirmacher P, Schmidt J, Buechler MW, Jaeger D, von Kalle C, Schemmer P. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation- HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8(1):349.

104. Howe S, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, Gilmour KC, Adams S, Thornhill SI, Parsley KL, Staal FJT, Gale RE, Linch DC, Bayford J, Brown L, Quaye M, Kinnon C, Ancliff P, Webb DK, Schmidt M, von Kalle C, Gaspar HB, Thrasher AJ. Insertional mutagenesis in combination with acquired somatic mutations leads to leukemogenesis following gene therapy of SCID-X1. J Clin Invest 2008; 118(9):3143-50.

105. Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Cherel Y, Chenuaud P, Schmidt M, von Kalle C, Moullier P, Snyder O. Adeno-associated Viral Vector Genomes Persist as Episomal Chromatin in Primate Muscle. Journal of Virology 2008; 82(16):7875-85.

106. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I, Braun S, Glimm H, von Kalle C. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nature Methods 2007; 4(12), 1051-1057.

107. Deichmann A, Hacein-Bey Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler M, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal F, Delabesse E, Villeval J, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, von Kalle C and Cavazzana-Calvo M. Vector Integration is Non-Random, Clustered and Influences the Fate of Lymphopoiesis in SCID-X1 Gene Therapy. J Clin Invest 2007; 117(8):2225-32.

108. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H, Schmidt S, Prinz C, Wissler M, King DJS, Zhang F, Parsley KL, Gilmour KC, Sinclair J, Bayford J, Peraj R, Pike-Overzet K, Staal FJT, de Ridder D, Kinnon C, Abel U, Wagemaker G, Gaspar B, Thrasher AJ and von Kalle C. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117(8):2241-9.

109. Abel U, Deichmann A, Bartholomae C, Schwarzwaelder K, Glimm H, Howe S, Thrasher A, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Fischer A, Jaeger D, von Kalle C, Schmidt M. Real-time definition of non-randomness in the distribution of genomic events. PLoS ONE 2007; 2(6):e570.

110. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B, Schmidt M, von Kalle C, Howe S, Thrasher AJ, Aiuti A, Ferrari G, Recchia A, Mavilio F. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007; 110(6):1770-8.

111. Ball CR, Pilz IH, Schmidt M, Fessler S, Williams DA, von Kalle C, Glimm H. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced intensity selection for MGMT P140K transgene expression. Blood 2007; 110(6):1779-87.

112. Will E, Bailey J, Schuesler T, Modlich U, Balcik B, Burzynski B, Witte D, Layh-Schmitt G, Rudolph C, Schlegelberger B, von Kalle C, Baum C, Sorrentino BP, Wagner LM, Kelly P, Reeves L, Williams DA. Importance of Murine Study Design for Testing Toxicity of Retroviral Vectors in Support of Phase I Trials. Mol Ther 2007; 15(4):782-91.

113. Kelly PF, Radtke S, von Kalle C, Balcik B, Bohn K, Mueller R, Schuesler T, Haren M, Reeves L, Cancelas JA, Leemhuis T, Harris R, Auerbach AD, Smith FO, Davies SM and Williams DA; Stem cell collection and gene transfer in Fanconi anemia. Mol Ther 2007; 15(1):211-9.

114. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply). Nature 2006; 443(7109):E6–E7.

115. Worsham DN, Schuesler T, von Kalle C, Pan D. In Vivo Gene Transfer into Adult Stem Cells in Unconditioned Mice by in Situ Delivery of a Lentiviral Vector. Mol Ther 2006; 14(4):514–24.

116. Mollmann H, Nef HM, Kostin S, von Kalle C, Pilz I; Weber M, Schaper J, Hamm CW, Elsasser A. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc Res 2006; 71(4):661–71.

117. Modlich U, Bohne J, Schmidt M, von Kalle C, Knob S, Schambach A, Baum C. Cell culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108(8):2545-53.

118. Fischer M, Schmidt M, Klingenberg S, Eaves CJ, von Kalle C, Glimm H. Short term repopulating cells with myeloid potential in human mobilized peripheral blood do not have a side population (SP) phenotype. Blood 2006; 108(6):2121-3.

119. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi LS, Benedicenti F, Ambrosi A, Di Serio C, Dogliosi C, von Kalle C, Naldini L. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology 2006; 24(6):687-96.

120. Schambach A, Galla M, Modlich U, Will E, Chandra S, Reeves L, Colbert M, Williams DA, von Kalle C, Baum C. Lentiviral vectors pseudotyped with murine ectropic envelope: increased biosafety and convenience in preclinical research. Exp Hematol 2006; 34(5):588-92.

121. Woods NB, Bottero V; Schmidt M, von Kalle C, Verma IM. Gene therapy: therapeutic gene causing lymphoma. Nature 2006; 440(7088):1123.

122. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, Restel BH, Ozawa MG, Moya CA, Rangel R Sun Y, Zaoui K, Schmidt M, von Kalle C, Weitzman MD, Gelovani JG, Pasqualini R, Arap W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006; 125(2):385-98.

123. Nowrouzi A, Dittrich M, Klanke C, Heinkelein M, Rammling M, Dandekar T, von Kalle C, Rethwilm A. Genome-wide mapping of foamy virus vector integrations into a human cell line. J Gen Virol 2006; 87(Pt5):1339-47.

124. Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, Naundorf S, Brinkmann A, Deichmann A, Fischer M, Ball C, Pilz I, Dunbar C, Du Y, Jenkins NA, Copeland NG, Lüthi U, Hassan M, Thrasher AJ, Hoelzer D, von Kalle C (co-corresponding and co-senior author), Seger R, Grez M. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1/EVI1, PRDM16 or SETBP1. Nature Medicine 2006; 12(4):401-9.

125. Bester AC, Schwartz M, Schmidt M, Garrigue A, Hacein-Bey-Abina S, Cavazzana-Calvo M, Ben-Porat N, von Kalle C, Fischer A, Kerem B. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther 2006; 13(13):1057-9.

126. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe S, Smith AJ, Buch P, Susie Barker, Durán Y, MacLaren RE, Anderson PN, Bartholomae C, Schmidt M, von Kalle C, Heckenlively JR, Kinnon C, Ali RR & Thrasher AJ. Effective gene therapy with non-integrating lentiviral vectors. Nature Medicine 2006; 12(3):348-53.

127. Seggewiss R, Pittaluga S, Adler RL, Guena FJ, Ferguson C, Pilz IH, Ryu B, Sorrentino BP, Young WS 3rd, Donahue RE, von Kalle C, Nienhuis AW, Dunbar CE. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 2006; 107(10):3865-7.

128. Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, Gregory LG, Nivsakar M, Themis M, Holder MV, Buckley SM, Dighe N, Ruthe AT, Mistry A, Bigger B, Rahim A, Nguyen TH, Trono D, Thrasher AJ, Coutelle C. Oncogenesis following delivery of a  nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 2005; 12(4):763-71.

129. Podsakoff GM, Engel BC, Carbonaro DA, Choi C, Smogorzewska EM, Bauer G, Selander D, Csik S, Wilson K, Betts MR, Koup RA, Nabel GJ, Bishop K, King S, Schmidt M, von Kalle C, Church JA, Kohn DB.  Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther 2005; 12(1):77-86.

130. Calmels B, Ferguson C, Laukkanen MO, Adler R, Faulhaber M, Kim HJ, Sellers S, Hematti P, Schmidt M, von Kalle C, Akagi K, Donahue RE, Dunbar CE.  Recurrent retroviral vector integration at the MDS1-EVI1 locus in non-human primate hematopoietic cells. Blood 2005; 106(7):2530-3.

131. Glimm H, Schmidt M, Fischer M, Schwarzwaelder K, Wissler M, Klingenberg S, Prinz C, Waller CF, Lange W, Eaves CJ, von Kalle C. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood 2005; 106(3):893–8.

132. Modlich U, Kustikova OS, Schmidt M, Rudolph C, Meyer J, Li Z, Kamino K, von Neuhoff N, Schlegelberger B, Kuehlcke K, Bunting KD, Schmidt S, Deichmann A, von Kalle C, Fehse B, Baum C. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 2005; 105(11):4235-46.  

133. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, Gilmour K, King D, Howe S, Sinclair J, Hue C, Carlier F, von Kalle C, de Saint Basile G, le Deist F, Fischer A, Cavazzana-Calvo M. Failure of SCID-X1 gene therapy in older patients. Blood 2005; 105(11):4255-7.

134. Glimm H, Schmidt M, Fischer M, Klingenberg S, Lange W, Waller CF, Eaves CJ, von Kalle C. Evidence of similar effects of short-term culture on the initial repopulating activity of mobilized peripheral blood transplants assessed in NOD/SCID-beta2microglobulin(null) mice and in autografted patients. Exp Hematol 2005; 33(1):20-5.

135. Schmidt M, Hacein-Bey-Abina S, Wissler M, Carlir F, Lim A, Prinz C, Glimm H, Andre-Schmutz I, Hue C, Garrigue A, Le Deist F, Lagresle C, Fischer A, Cavazzana-Calvo M, von Kalle C. Clonal Evidence for the Transduction of CD34+ Cells with Lymphomyeloid Differentiation Potential and Self-Renewal Capacity in the SCID-XI Gene Therapy Trial. Blood 2005; 105(7):2699-706.

136. Milsom MD, Duxbury R, Gagen D, Humphries RK, Schmidt M, von Kalle C, Fairbairn LJ. Overexpression of HOXB4 confers a myelo-erythroid differentiation delay in vitro. Leukemia 2005; 19(1):148-53.

137. Laukkanen MO, Kuramoto K, Calmels B, Takatoku M, von Kalle C, Donahue RE, Dunbar CE. Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells. Blood 2005; 105(3):1010-1015.

138. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ.  Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364(9452):2155-6.

139. Hematti P, Hong BK, Ferguson C, Adler R, Hanawa, Sellers S, Holt IE, Eckfeldt CE, Sharma Y, Schmidt M, von Kalle C, Persons DA, Billings EM, Verfaillie CM, Nienhuis AW, Wolfsberg TG, Dunbar CE, Calmels B.  Distinct Genomic Integration of MLV and SIV vectors in primate Hematopoietic Stem and Progenitor Cells. PLoS Biol 2004; 2(12):e423.

140. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Calvo M.  LMO and gene therapy for severe combined immunodeficiency. N Engl J Med 2004; 350(24):2526-7; author reply 2526-7.

141. Kuramoto K, Follman D, Hematti P, Sellers S, Laukkanen MO, Seggewiss R, Metzger ME, Krouse A, Donahue RE, von Kalle C, Dunbar CE. The impact of low-dose busulfan on clonal dynamics in nonhuman primates. Blood 2004; 104(5):1273-80.

142. Kiem HP, Sellers S, Thomasson B, Morris JC, Tisdale JF, Horn PA, Hematti P, Adler R, Kuramoto K, Calmels B, Bonifacino A, Hu J, von Kalle C, Schmidt M, Sorrentino B, Nienhuis A, Blau CA, Andrews RG, Donahue RE, Dunbar CE. Long-Term Clinical and Molecular Follow-up of Large Animals Receiving Retrovirally Transduced Stem and Progenitor Cells: No Progression to Clonal Hematopoiesis or Leukemia. Mol Ther 2004; 9(3):389-95.

143. Kuramoto K, Follmann DA, Hematti P, Sellers S, Agricola BA, Metzger ME, Donahue RE, von Kalle C, Dunbar CE. Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood 2004; 103(11):4070-7.

144. Gao C, Kang EM, Kuramoto K, Agricola BA, Metzger M, von Kalle C, Donahue RE, Tisdale, JF. Retrovirally transduced muscle derived cells contribute to hematopoiesis at very low levels in the non-human primate model. Mol Ther 2003; 8(6):974-80.

145. Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA, Schmidt M, Georges GE, von Kalle C, Kiem HP. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112(10):1581-8.

146. Hacein-Bey-Abina S*, von Kalle C*, (cofirst author*) Schmidt M*, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644):415-9.

147. Schmidt M, Glimm H, Wissler M, Hoffmann G, Olsson K, Sellers S, Carbonaro D, Tisdale JF, Leurs C, Hanenberg H, Dunbar CE, Kiem HP, Karlsson S, Kohn DB, Williams D, von Kalle C. Efficient characterization of retro-, lenti-, and foamyvector-transduced cell populations by high-accuracy insertion site sequencing. Annals of the  New York Academy of Science 2003; 996:112-21.

148. Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M, Lindemann D, von Kalle C, Rethwilm A, Williams DA, Hanenberg H. Comparison of Three Retroviral Vector Systems for Transduction of Nonobese Diabetic/Severe Combined Immunodeficiency Mice Repopulating Human CD34(+) Cord Blood Cells. Hum Gene Ther 2003; 14(6):509-19.

149. Schmidt M, Carbonaro D, Speckmann C, Wissler M, Bohnsack J, Elder M, Aronow B, Nolta JA, Kohn DB and von Kalle C. Clonality Analysis after Retroviral-Mediated Gene Transfer To CD34+ Cells from the Cord Blood of ADA-Deficient SCID Neonates. Nat Med 2003; 9(4):463-8.

150. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348(3):255-6.

151. Woods NB, Johan Flygare F, Muessig A, Schmidt M, Olsson K, Salmon P, Trono D, von Kalle C (corresponding author), Karlsson S. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood. 2003; 101(4):1284-9.

152. Ailles L, Schmidt M, Santoni de Sio F, Glimm H, Cavalieri S, Bruno S, Piacibello W, von Kalle C, Naldini L. Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-Potent Long-Term Repopulating Hematopoietic Cells, Mol Ther 2002; 6(5):615-26.

153. Schmidt M, Zickler P, Hoffmann G, Haas S, Wissler M, Muessig A, Glimm H, Wu T, Tisdale JF, Dunbar CE, and von Kalle C. Polyclonal long-term repopulating stem cell clones in a primate model. Blood 2002; 100(8):2737-2743.

154. Neff T, Horn PA, Valli VE, Gown AM, Wardwell S, Wood BL, von Kalle C, Schmidt M, Peterson LJ, Morris JC, Richard RE, Clackson T, Kiem HP, Blau CA. Pharmacologically regulated in vivo selection in a large animal. Blood 2002; 100(6): 2026-31.

155. Spyridonidis A, Otto F, Kraft A, von Kalle C. Antibiotics for weight loss, osteolysis, hepatic and adrenal tumours. Lancet 2002; 359(9320):1828.

156. Li Z, Düllmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kühlcke K, Eckert HG, Fehse B, Baum C. Murine leukemia induced by retroviral gene marking. Science 2002; 296(5567):497.

157. Glimm H, Tang P, Clark-Lewis I, von Kalle C, Eaves C. Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice. Blood 2002; 99(9):3454-7.

158. Schmidt M, Glimm H, Lemke N, Muessig A, Speckmann C, von Kalle C. A model for the detection of clonality in marked hematopoietic stem cells, Annals of the New York Academy of Sciences 2001; 938:146-55.

159. Schmidt M, Hoffmann G, Wissler M, Müßig A, Lemke N, Glimm H, Hesemann CU, von Kalle C. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Human Gene Therapy 2001; 12(7): 743-9.

160. Glimm H, Eisterer W, Lee K, Cashman J, Holyoake TL, Nicolini F, Shultz LD, von Kalle C, Eaves CJ. Previously undetected human hematopoietic cell populations with short term repopulating activity selectively engraft NOD/SCID-ß2 microglobulin-null mice. J Clin Invest 2001; 107(2):199-206.

161. Glimm H, Flügge K, Möbest D, Hofmann VM, Postmus J, Henschler R, Lange W, Finke J, Kiem HP, Mertelsmann R, von Kalle C. Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, non-concentrated vector containing medium. Human Gene Therapy. 1998; 9(6):771-8.

162. Glimm H, Kiem HP, Darowsky B, Storb R, Wolf J, Mertelsmann R, von Kalle C. Efficient gene transfer in primitive CD34+/CD38- human bone marrow cells reselected after long-term exposure to GALV pseudotyped retrovirus vector. Human Gene Therapy. 1997; 8(17):2079-86.

163. Schuening FG, von Kalle C, Appelbaum FR, Deeg HJ, Pepe M, Gooley T, Graham TC, Hackman R, Storb R. Recombinant stem cell factor, a c-kit ligand, accelerates hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. Exp Hematol. 1997; 25(12):1240-5.

164. Rommel B, Rogalla P, Jox A, von Kalle C, Kazmierczak B, Wolf J, Bullerdiek J. HMGI-C, a member of the high mobility group family of proteins, is expressed in hematopoietic stem cells and in leukemic cells. Leuk Lymphoma 1997; 26(5-6):603-7.

165. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood. 1996; 87(8):3418-28.

166. Kiem HP, Darovsky B, von Kalle C, Goehle S, Stewart D, Graham T, Hackman R, Appelbaum FR, Deeg HJ, Miller AD, Storb R, Schuening FG. Long-term persistence of canine marrow repopulating cells genetically marked by retrovirus vectors without side effects. Human Gene Therapy. 1996; 7(1):89-96.

167. Barquinero J, Kiem HP, von Kalle C, Darovsky B, Goehle S, Graham T, Seidel K, Gooley T, Barranger J, Storb R, Schuening FG. Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood. 1995; 85(5):1195-201.

168. von Kalle C, Kiem HP, Goehle S, Darovsky B, Heimfeld S, Torok-Storb B, Storb R, Schuening FG. Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood. 1994; 84(9):2890-7.

169. Kiem HP, Darovsky B, von Kalle C, Goehle S, Stewart D, Graham T, Hackman R, Appelbaum FR, Deeg HJ, Miller AD, Storb R, Schuening FG. Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells. Blood. 1994; 83(6):1467-73.

170. Kapp U, Wolf J, Hummel M, Pawlita M, von Kalle C, Dallenbach F, Schwonzen M, Krueger GR, Muller LN, Fonatsch C, et al. Hodgkin's lymphoma-derived tissue serially transplanted into severe combined immunodeficient mice. Blood. 1993; 82(4):1247-56.

171. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, Engert A, Kapp U, Fonatsch C, Komitowski D, Feaux dLW, et al: Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer. 1992; 52(6):887-91.

172. Kapp U, Wolf J, von Kalle C, Tawadros S, Rottgen A, Engert A, Fonatsch C, Stein H, Diehl V. Preliminary report: growth of Hodgkin's lymphoma derived cells in immune compromised mice. Ann Oncol.1992; 3 Suppl 4:21-3.

173. Kapp U, Wolf J, von Kalle C, Stein H, Fonatsch C, Schell FE, Diehl V. Recent efforts to establish an in vivo model as a new experimental tool in the study of Hodgkin's disease. Eur J Cancer, 1992; 28A(8-9):1408-11.

174. Jucker M, Abts H, Li W, Schindler R, Merz H, Gunther A, von Kalle C, Schaadt M, Diamantstein T, Feller AC, et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood. 1991; 77(11):2413-8.

175. Katay I, Wirnitzer U, Burrichter H, von Kalle C, Schell FE, Diehl V, Schaadt M. L428 cells derived from Hodgkin's disease produce E rosette-inhibiting factor. Blood. 1990; 76:791-796.

1. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Bougnères P, Schmidt M, von Kalle C, Fischer A, Cavazzana-Calvo M, Aubourg P. Lentiviral hematopoietic cell gene therapy for x-linked adrenoleukodystrophy. Methods Enzymol. 2012; 507:187-98.

2. Paruzynski A, Glimm H, Schmidt M, von Kalle C. Analysis of the clonal repertoire of gene-corrected cells in gene therapy. Methods Enzymol. 2012; 507:59-87.

3. Nowrouzi A, Glimm H, von Kalle C, Schmidt M. Retroviral vectors: post entry events and genomic alterations. Viruses 2011; 3(5):429-55.

4. Tolar J, Adair JE, Antoniou M, Bartholomae CC, Becker PS, Blazar BR, Bueren J, Carroll T, Cavazzana-Calvo M, Clapp DW, Dalgleish R, Galy A, Gaspar HB, Hanenberg H, von Kalle C, Kiem HP, Lindeman D, Naldini L, Navarro S, Renella R, Rio P, Sevilla J, Schmidt M, Verhoeyen E, Wagner JE, Williams DA, Thrasher AJ. Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. Mol Ther 2011; 19(7):1193-8.

5. Maier P, von Kalle C, Laufs S. Retroviral vectors for gene therapy. Future Microbiol 2010; 5:1507-23.

6. Langer P, Regenbogen J, Bauser C, Schmidt M, von Kalle C. Analyse retroviraler Insertionsstellen zur Erhöhung der Sicherheit somatischer Gentherapie. BIOspektrum. 2006; 3:170-172.

7. von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. Semin Hematol. 2004; 41(4):303-18.

8. von Kalle C, Baum C, Williams DA.  Lenti in Red:  Progress in Gene Therapy for Human Hemoglobinopathies.  J Clin Invest. 2004; 114(7):889-91.

9. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA. Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its Consequences. Mol Ther. 2004; 9(1): 5-13.

10. Baum C, von Kalle C. Gene therapy targeting hematopoietic cells: better not leave it to chance.  Acta Haematol. 2003; 110(2-3):107-9.  

11. Baum C, Düllmann J, Li Z, Fehse B, Meyer J, Williams D. A, von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood. 2003; 101(6):2099-114.

12. Shi PA, Hematti P, von Kalle C, Dunbar CE: Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model. Oncogene. 2002; 21(21):3274-83.

13. Bosse R, Kulmburg P, von Kalle C, Engelhardt M, Dwenger A, Rosenthal F, Schulz G: Production of stem-cell transplants according to good manufacturing practice. Ann Hematol. 2000; 79(9):469-76.

14. von Kalle C, Glimm H, Schulz G, Mertelsmann R, Henschler R: New developments in hematopoietic stem cell expansion. Current Opinion in Hematology. 1998; 5(1): 79-86.

15. Kiem HP, von Kalle C, Schuening F, Storb R: Gene therapy and bone marrow transplantation. Current Opinion in Oncology, 1995; 7:107-114.

16. von Kalle C, Diehl V: Hodgkin's disease: analysis of cell line data. Int Rev Exp Pathol. 1992; 33:185-203.

17. Diehl V, von Kalle C, Fonatsch C, Tesch H, Juecker M, Schaadt M: The cell of origin in Hodgkin's disease. Semin Oncol. 1990; 17(6):660-72.

1. Bartholomae CC, Glimm H, von Kalle C, Schmidt M. Insertion Site Pattern: Global approach by linear amplification-mediated PCR (LAM-PCR) and mass sequencing. In: Y. Bigot (ed.), Mobile Genetic Elements: Protocols and Genomic Applications, Methods Mol Biol 2012; 859:255-65; Springer Science + Business Media, LLC 2012.

2. Bartholomae CC, Kirsten R, Glimm H, Schmidt M, von Kalle C. Retroviral Vectors and Integration Analysis. In: R. Herzog, S. Zolothukin: A Guide to Human Gene Therapy, World Scientific Publishing Co. Pte. Ltd., pp.37-52, 2010.

3. Schuesler T, Reeves L, von Kalle C, Elke Grassman E. Copy Number Determination of Genetically-Modified Hematopoietic Stem Cells. In: C. Baum (ed.), Methods in Molecular Biology, Methods and Protocols, Methods Mol Biol 2009; 506:281-98; Humana Press 2009.

4. Schmidt M, Schwarzwaelder K, Bartholomae C, Glimm H, von Kalle C. Detection of retroviral integration sites by linear amplification mediated PCR 107 (LAM-PCR) and tracking of individual integration clones in different samples. In: C. Baum (ed.), Methods in Molecular Biology, Methods and Protocols, Methods Mol Biol 2009; 506:363-72; Humana Press 2009.

5. Hu J, Schmidt M, Deichmann A, Glimm H, von Kalle C: The Clonal Activity of Marked Hematopoietic Stem Cells. In: A.D. Ho, R. Hoffmann, E.D. Zanjani (eds), Stem Cell Transplantation, WILEY-VCH 2006.

6. von Kalle C: Zellbiologische und molekulare Stammzellforschung in der Medizin. In: Blum E and Siegenthaler W (eds): Zell- und Molekularbiologie in der Inneren Medizin – Grundlagen und klinische Relevanz. Thieme, Stuttgart p. 67-69, 2006.

7. von Kalle C, Mertelsmann R: The status of gene transfer in clinical hematopoietic stem cell transplantation. In Rowe, Lazarus, Carella: Handbook of bone marrow transplantation. Martin Dunitz Ltd, London 2000.

8. Glimm H, von Kalle C, Henschler R, and Mertelsmann R: Hematopoietic ex vivo gene transfer. In: Gene Therapy. (Eds, Sobol R.E., Scanlon K.J., and Nestaas E.) p.195, 1998.

9. von Kalle C, Kiem HP, Schuening FG: Retroviral mediated gene transfer and gene therapy. In Levitt, Mertelsmann (eds): Therapeutic applications of hematopoietic stem cells, 1995.

10. Diehl V, von Kalle C, Fonatsch C, Tesch H, Schaadt M: The cell biology of Hodgkin’s disease. In Oxford Textbook of Oncology, 1995.

11. von Kalle C, Diehl V, Jücker M, Tesch H, Fonatsch C, Pfreundschuh M, Schaadt M: New developments in the pathogenesis of Hodgkin´s disease. In Somers, Henry-Amar, Meerwaldt, Carde (eds): Treatment strategies in Hodgkin´s disease. Colloque Inserm 196:3-15, 1990.